Houlihan Lokey Estimates Cut by Morgan Stanley as Sponsor M&A Recovery Lags

MT Newswires Live07-09 20:34

Investment banking advisory firms are expected to benefit from large corporate M&A activity, though a slower recovery in sponsor-backed deals could weigh on the sector ahead of Q2, Morgan Stanley said in a note on Thursday.

The firm lowered its estimates for Houlihan Lokey (HLI) and Lazard (LAZ) ahead of Q2 earnings, while remaining more constructive on Evercore (EVR) and Moelis & Company (MC).

Morgan Stanley cut its Q2 EPS estimate for Houlihan Lokey by 17% to $1.73, citing weaker corporate finance revenue and a higher tax rate, and also lowered its fiscal 2027 and 2028 EPS forecasts.

The firm also trimmed its stock price target for Houlihan Lokey to $187 from $193.

Morgan Stanley said Evercore and Moelis are its preferred names heading into earnings, expecting Evercore to benefit from strong large-cap strategic M&A, equity capital markets activity and trading, while Moelis is viewed as best positioned to deliver strong top-line results.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment